Emmecell dosed the first patient on Wednesday in EMERALD, a Phase 2 trial testing whether a single injection of magnetically guided corneal endothelial cells can restore vision in corneal edema — a potential alternative to donor-tissue transplant surgery, Eyewire++ reported.
The trial, run across multiple US sites, is randomized, double-masked, and placebo-controlled — meaning neither patients nor assessors know who received cells and who received a cell-free vehicle injection. That design matters: for a condition where vision can fluctuate on its own, only a blinded, controlled study can separate true treatment effect from expectation.
EO2002 is an investigational allogeneic human corneal endothelial cell therapy — cells from a donor line, not the patient’s own — delivered by a single intracameral injection, meaning an injection directly into the fluid-filled anterior chamber of the eye. The company’s Magnetic Cell Delivery platform pairs magnetically labeled cells with an external magnetic patch worn to guide the cells toward the corneal endothelium and improve their retention there.
Why it matters: corneal endothelial cells form the inner pumping layer that keeps the cornea clear. When they are lost — as in Fuchs endothelial corneal dystrophy or after cataract surgery (pseudophakic bullous keratopathy) — fluid builds up, the cornea swells, and vision blurs. Advanced disease is typically treated with endothelial keratoplasty, a partial-thickness transplant that depends on donor tissue and specialized surgery.

Trial tests single injection versus transplant
- EO2002 is not approved. It is experimental, and this trial is designed to find out whether it works at all.
- The idea is one injection instead of transplant surgery — using donor-derived cells steered into place by a magnet on the outside of the eye.
- Success in this trial would mean at least a 15-letter gain on a standard eye chart at 26 weeks, measured against a placebo group.
How the EMERALD trial will judge success
According to the ClinicalTrials.gov registration, approximately 105 participants will be enrolled at multiple US sites. Each receives a single intracameral injection of either 150,000 cells, 500,000 cells, or placebo. The primary endpoint is the proportion of eyes achieving at least a 15-letter improvement in best-corrected visual acuity — vision tested while wearing the patient’s best glasses or contact lenses, using the ETDRS letter chart — from baseline at 26 weeks.
Secondary assessments include mean change in visual acuity, central corneal thickness (a direct measure of corneal swelling), and safety, with follow-up through 52 weeks. Emmecell intends EMERALD to be the first of two trials in a planned registrational program, Eyewire++ reported.
Strict eligibility and exclusion criteria listed
The trial registration sets strict eligibility. Enrolled participants must have symptomatic central corneal edema from endothelial dysfunction, an ETDRS best-corrected visual acuity between 20 and 65 letters, and central corneal thickness of at least 600 micrometers (or documented edema on imaging), and must already be surgical candidates for corneal transplantation.
Exclusions are extensive: prior herpetic eye infection, severe dry eye disease such as Sjögren’s, central corneal scarring, keratoconus, prior vitrectomy, prior corneal refractive surgery, prior glaucoma surgery or pressure-lowering implants, and certain intraocular lens types. In practice, the study is targeting patients whose disease is otherwise straightforward — a deliberate choice to keep the result interpretable.
Regulatory standing and what the company says
The FDA granted EO2002 Regenerative Medicine Advanced Therapy (RMAT) designation in July 2026, a status intended to speed development of regenerative therapies for serious conditions, Eyewire++ and Business Wire both reported. RMAT designation is not approval; it provides earlier and more frequent FDA interaction during development.
“Starting dosing in EMERALD is an important step toward evaluating a different treatment approach for patients with corneal endothelial disease,” said Ramin Valian, Chief Executive Officer of Emmecell, in the company’s announcement.
“Our goal is to restore corneal function through a single injection and reduce the burden of transplant surgery. This randomized, placebo-controlled study is designed to generate the evidence needed to evaluate that potential and guide the next stage of EO2002’s development. We thank the patients, investigators and study teams making this work possible.”
“Corneal endothelial dysfunction can significantly affect patients’ vision and daily activities, and additional treatment options are needed,” said Jennifer Nottage, MD, an investigator in the EMERALD study, according to the company’s release. “EMERALD will help us understand whether an injection of magnetic corneal endothelial cells can improve vision and corneal clarity. We are pleased to contribute to this evaluation.”
No efficacy data exist yet
Every result reported so far is about trial design, not outcomes. No efficacy data from EMERALD exist yet, and EO2002, as the company’s own release states, remains investigational and has not been approved for commercial use. A placebo arm means some participants will receive an injection with no cells — a standard approach that also captures any effect of the injection procedure itself.
Funding and bias transparency: the trial is sponsored by Emmecell, the therapy’s developer, per the company announcement and the ClinicalTrials.gov record. Company-sponsored trials are the normal pathway for investigational products, but readers should weigh results from this program with that sponsorship in mind until independent replication exists.
Treatment available only through trial enrollment
Because EO2002 is available only within this clinical trial, no patient can currently request it outside enrollment. People with corneal edema who are interested should discuss with their ophthalmologist whether they meet trial criteria — including the specific exclusions listed in the registration, such as prior vitrectomy, certain lens implants, or a history of glaucoma surgery.
Anyone with worsening blurred vision, corneal swelling, or eye pain should seek evaluation by an eye-care professional rather than wait for new therapies; endothelial keratoplasty remains the established standard of care for advanced disease, as the source materials describe. Trial-site contact details are available through the study’s ClinicalTrials.gov listing.
Where this leaves corneal patients
The strongest fact in this story is structural: donor corneas are a finite resource, and every patient enrolled in EMERALD is someone who would otherwise be waiting for or undergoing transplant surgery. Whether a single magnetically guided injection can match that outcome will be measured at 26 weeks — with two dose levels and a placebo arm standing between the promise and the evidence.
References
- ClinicalTrials.gov (US National Library of Medicine) — Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (EMERALD), NCT07729137: trial record and study details
- Eyewire++ — Emmecell Doses First Patient in Phase 2 EMERALD Trial Evaluating EO2002 for Corneal Edema (November 18, 2026)
- Business Wire (via Morningstar) — Emmecell Announces First Patient Dosed in EMERALD Study of Magnetic Cell Therapy for Corneal Endothelial Disease: press release